










<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/css" href="http://52.214.119.220/wiki/skins/common/feed.css?97"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
		<id>http://52.214.119.220/wiki/index.php?action=history&amp;feed=atom&amp;title=4j96</id>
		<title>4j96 - Revision history</title>
		<link rel="self" type="application/atom+xml" href="http://52.214.119.220/wiki/index.php?action=history&amp;feed=atom&amp;title=4j96"/>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;action=history"/>
		<updated>2026-04-03T18:46:42Z</updated>
		<subtitle>Revision history for this page on the wiki</subtitle>
		<generator>MediaWiki 1.11.2</generator>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=3875728&amp;oldid=prev</id>
		<title>OCA at 15:38, 20 September 2023</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=3875728&amp;oldid=prev"/>
				<updated>2023-09-20T15:38:03Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 15:38, 20 September 2023&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 4:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 4:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [https://proteopedia.org/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [https://proteopedia.org/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot; id=&amp;quot;ligandDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='method'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Empirical_models|Method:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot; id=&amp;quot;methodDat&amp;quot;&amp;gt;X-ray diffraction, [[Resolution|Resolution]] 2.2972&amp;amp;#8491;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot; id=&amp;quot;ligandDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[https://proteopedia.org/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [https://pdbe.org/4j96 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [https://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[https://proteopedia.org/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [https://pdbe.org/4j96 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [https://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=3670228&amp;oldid=prev</id>
		<title>OCA at 11:00, 24 November 2022</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=3670228&amp;oldid=prev"/>
				<updated>2022-11-24T11:00:08Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 11:00, 24 November 2022&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right'caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right'caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://en.wikipedia.org/wiki/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human Human&lt;/del&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann.ac.il/oca-docs&lt;/del&gt;/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://en.wikipedia.org/wiki/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo_sapiens Homo sapiens&lt;/ins&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proteopedia&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org&lt;/ins&gt;/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;quot; id=&amp;quot;ligandDat&lt;/ins&gt;&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proteopedia&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org&lt;/ins&gt;/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://pdbe.org/4j96 PDBe], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&lt;/del&gt;&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann.ac.il/oca-docs&lt;/del&gt;/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://pdbe.org/4j96 PDBe], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http&lt;/del&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123500 123500&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123150 123150&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/101200 101200&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/101600 101600&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123790 123790&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/609579 609579&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/149730 149730&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/207410 207410&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/614592 614592&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123500 123500]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123150 123150]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/101200 101200]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/101600 101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123790 123790]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/609579 609579]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/149730 149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/207410 207410]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/614592 614592]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http&lt;/del&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 25:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;receptor 3D &lt;/ins&gt;receptor|Fibroblast growth factor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;receptor 3D &lt;/ins&gt;receptor]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo sapiens&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;M&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Atp binding]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Kinase domain fold consisting of n- and c-lobe]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor tyrosine kinase]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Transferase&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=3021850&amp;oldid=prev</id>
		<title>OCA at 08:55, 3 April 2019</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=3021850&amp;oldid=prev"/>
				<updated>2019-04-03T08:55:48Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 08:55, 3 April 2019&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right' caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right'caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;with sequence from [http://en.wikipedia.org/wiki/Human Human]&lt;/ins&gt;. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [http://pdbe.org/4j96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [http://pdbe.org/4j96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 29:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 30:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Human]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=2701924&amp;oldid=prev</id>
		<title>OCA at 09:24, 2 January 2017</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=2701924&amp;oldid=prev"/>
				<updated>2017-01-02T09:24:32Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 09:24, 2 January 2017&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Strucure &lt;/del&gt;of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Structure &lt;/ins&gt;of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right' caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right' caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;with sequence from [http://en.wikipedia.org/wiki/Human Human]&lt;/del&gt;. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [http://pdbe.org/4j96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [http://pdbe.org/4j96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 30:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 29:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Human]]&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=2633354&amp;oldid=prev</id>
		<title>OCA at 19:20, 4 August 2016</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=2633354&amp;oldid=prev"/>
				<updated>2016-08-04T19:20:24Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 19:20, 4 August 2016&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right' caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='4j96' size='340' side='right' caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo_sapiens Homo sapiens&lt;/del&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human Human&lt;/ins&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo sapiens&lt;/del&gt;])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;HUMAN&lt;/ins&gt;])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;], [http://pdbe.org/4j96 PDBe&lt;/ins&gt;], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4j96 ProSAT&lt;/ins&gt;]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 21:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, a database of the U.S. National Library of Medicine.&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, a database of the U.S. National Library of Medicine.&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 4j96&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 28:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 30:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo sapiens&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=2141274&amp;oldid=prev</id>
		<title>OCA at 12:27, 21 December 2014</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=2141274&amp;oldid=prev"/>
				<updated>2014-12-21T12:27:15Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 12:27, 21 December 2014&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{STRUCTURE_4j96|  PDB=4j96  |  SCENE=  }} &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;=&lt;/del&gt;==Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.===&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;StructureSection load&lt;/ins&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'4j96' size='340' side='right' caption='[[4j96]], [[Resolution|resolution]] 2.30&amp;amp;Aring;' scene=''&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{ABSTRACT_PUBMED_23871672}}&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Structural highlights ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[4j96]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4J96 FirstGlance]. &amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Disease==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ACP:PHOSPHOMETHYLPHOSPHONIC+ACID+ADENYLATE+ESTER'&amp;gt;ACP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=FLC:CITRATE+ANION'&amp;gt;FLC&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=MG:MAGNESIUM+ION'&amp;gt;MG&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[2psq|2psq]], [[2pvf|2pvf]], [[4j95|4j95]], [[4j97|4j97]], [[4j98|4j98]], [[4j99|4j99]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;BEK, FGFR2, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 Homo sapiens])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4j96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4j96 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4j96 RCSB], [http://www.ebi.ac.uk/pdbsum/4j96 PDBsum]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/table&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/entry/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/entry/614592 614592]]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/entry/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/entry/614592 614592]]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The basal (ligand-independent) kinase activity of receptor tyrosine kinases (RTKs) promotes trans-phosphorylation on activation loop tyrosines upon ligand-induced receptor dimerization, thus upregulating intrinsic kinase activity and triggering intracellular signaling. To understand the molecular determinants of intrinsic kinase activity, we used X-ray crystallography and NMR spectroscopy to analyze pathogenic FGF receptor mutants with gradations in gain-of-function activity. These structural analyses revealed a &amp;quot;two-state&amp;quot; dynamic equilibrium model whereby the kinase toggles between an &amp;quot;inhibited,&amp;quot; structurally rigid ground state and a more dynamic and heterogeneous active state. The pathogenic mutations have different abilities to shift this equilibrium toward the active state. The increase in the fractional population of FGF receptors in the active state correlates with the degree of gain-of-function activity and clinical severity. Our data demonstrate that the fractional population of RTKs in the active state determines intrinsic kinase activity and underscore how a slight increase in the active population of kinases can have grave consequences for human health.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Function==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Cracking the Molecular Origin of Intrinsic &lt;/ins&gt;Tyrosine &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Kinase Activity through Analysis of Pathogenic Gain&lt;/ins&gt;-&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;of&lt;/ins&gt;-&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Function Mutations.&lt;/ins&gt;,&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Chen H&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Huang Z&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Dutta K&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Blais S&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Neubert TA&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Li X&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Cowburn D&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Traaseth NJ&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Mohammadi M Cell Rep&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2013 Jul 25;&lt;/ins&gt;4&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;(2):376&lt;/ins&gt;-&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;84&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;doi: 10.1016&lt;/ins&gt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;j&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;celrep.2013.06.025&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Epub 2013&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Jul 18&lt;/ins&gt;. PMID:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;23871672&lt;/ins&gt;&amp;lt;ref&amp;gt;PMID:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;23871672&lt;/ins&gt;&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] &lt;/del&gt;Tyrosine-&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;protein kinase that acts as cell&lt;/del&gt;-&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;differentiation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;migration and apoptosis&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;and in the regulation of embryonic development. Required for normal embryonic patterning&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;trophoblast function&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;limb bud development&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;lung morphogenesis&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proliferation and apoptosis&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;and is required for normal skeleton development&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,&lt;/del&gt;4&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;,5&lt;/del&gt;-&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;trisphosphate&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1&lt;/del&gt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;internalization and degradation lead to aberrant signaling&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;&lt;/del&gt;PMID:&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &lt;/del&gt;&amp;lt;ref&amp;gt;PMID:&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;16384934&lt;/del&gt;&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==About this Structure==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, &lt;/ins&gt;a &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;database of the U&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;S&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;National Library of Medicine&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[4j96]] is &lt;/del&gt;a &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2 chain structure with sequence from [http://en&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;wikipedia&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org/wiki/Homo_sapiens Homo sapiens]&lt;/del&gt;. &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Full crystallographic information is available from [http:&lt;/del&gt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;/oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;&lt;/ins&gt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;div&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Reference&lt;/del&gt;==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;See Also&lt;/ins&gt;==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref group&lt;/del&gt;=&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;quot;xtra&amp;quot;&amp;gt;PMID:023871672&amp;lt;/ref&amp;gt;&lt;/del&gt;&amp;lt;references &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;group=&amp;quot;xtra&amp;quot;&lt;/del&gt;/&amp;gt;&amp;lt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;references&lt;/del&gt;/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;= References ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;__TOC__&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;StructureSection&lt;/ins&gt;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Homo sapiens]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Homo sapiens]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi, M&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi, M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Atp binding]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Atp binding]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Kinase domain fold consisting of n- and c-lobe]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Kinase domain fold consisting of n- and c-lobe]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Transferase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Transferase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1829556&amp;oldid=prev</id>
		<title>OCA at 20:51, 7 August 2013</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1829556&amp;oldid=prev"/>
				<updated>2013-08-07T20:51:18Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 20:51, 7 August 2013&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'''Unreleased structure'''&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{STRUCTURE_4j96|  PDB=4j96  |  SCENE=  }} &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;===Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.===&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;{{ABSTRACT_PUBMED_23871672}}&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;4j96 &lt;/del&gt;is &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ON HOLD &lt;/del&gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;until Paper Publication&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Disease==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. &lt;/ins&gt;The &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/entry/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/&lt;/ins&gt;entry&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;/614592 614592]]. BBDS &lt;/ins&gt;is &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;/ins&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Authors&lt;/del&gt;: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Chen&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;H&lt;/del&gt;., &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Mohammadi&lt;/del&gt;, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;M&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Function==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http&lt;/ins&gt;:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;//www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;differentiation, migration and apoptosis, and in the regulation of embryonic development&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Required for normal embryonic patterning&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;trophoblast function&lt;/ins&gt;, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;limb bud development, lung morphogenesis, osteogenesis and skin development&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt;  &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Description&lt;/del&gt;: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Crystal Strucure of FGF &lt;/del&gt;Receptor &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain&lt;/del&gt;-of-&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Function K659M Mutation Identified in Cervical Cancer.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==About this Structure==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[4j96]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4J96 OCA]. &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Reference==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref group=&amp;quot;xtra&amp;quot;&amp;gt;PMID:023871672&amp;lt;/ref&amp;gt;&amp;lt;references group=&amp;quot;xtra&amp;quot;/&amp;gt;&amp;lt;references/&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Homo sapiens]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category&lt;/ins&gt;: Receptor &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;protein&lt;/ins&gt;-&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;tyrosine kinase]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Chen, H.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Mohammadi, M.]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Atp binding]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Kinase domain fold consisting &lt;/ins&gt;of &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;n&lt;/ins&gt;- &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;and c-lobe]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor tyrosine kinase]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Transferase]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1821719&amp;oldid=prev</id>
		<title>OCA at 04:43, 18 July 2013</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1821719&amp;oldid=prev"/>
				<updated>2013-07-18T04:43:09Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 04:43, 18 July 2013&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j96 is ON HOLD &lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 4j96 is ON HOLD &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; until Paper Publication&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Chen, H., Mohammadi, M.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Chen, H., Mohammadi, M.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1728303&amp;oldid=prev</id>
		<title>OCA: Protected &quot;4j96&quot; [edit=sysop:move=sysop]</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1728303&amp;oldid=prev"/>
				<updated>2013-02-27T14:25:53Z</updated>
		
		<summary type="html">&lt;p&gt;Protected &amp;quot;&lt;a href=&quot;/wiki/index.php/4j96&quot; title=&quot;4j96&quot;&gt;4j96&lt;/a&gt;&amp;quot; [edit=sysop:move=sysop]&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 14:25, 27 February 2013&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	<entry>
		<id>http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1728302&amp;oldid=prev</id>
		<title>OCA: New page: '''Unreleased structure'''  The entry 4j96 is ON HOLD   Authors: Chen, H., Mohammadi, M.  Description: Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gai...</title>
		<link rel="alternate" type="text/html" href="http://52.214.119.220/wiki/index.php?title=4j96&amp;diff=1728302&amp;oldid=prev"/>
				<updated>2013-02-27T14:25:52Z</updated>
		
		<summary type="html">&lt;p&gt;New page: '''Unreleased structure'''  The entry 4j96 is ON HOLD   Authors: Chen, H., Mohammadi, M.  Description: Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gai...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;'''Unreleased structure'''&lt;br /&gt;
&lt;br /&gt;
The entry 4j96 is ON HOLD &lt;br /&gt;
&lt;br /&gt;
Authors: Chen, H., Mohammadi, M.&lt;br /&gt;
&lt;br /&gt;
Description: Crystal Strucure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.&lt;/div&gt;</summary>
		<author><name>OCA</name></author>	</entry>

	</feed>